Many Cancer Patients Not Receiving Genomic Testing Despite Treatment Advances

Genomic testing for cancer patients involves sequencing tumor DNA to detect mutations that can guide personalized treatments. According to STAT News, many patients do not receive this testing despite its potential to inform therapy choices. The testing can reveal eligibility for targeted drugs or immunotherapies that address specific genetic alterations in tumors.

Advances in cancer therapies have increased the relevance of genomic testing. New drugs target particular mutations, such as those in EGFR or BRAF genes, improving outcomes for subsets of patients. However, barriers including cost, access, and awareness limit its use across patient populations.

from recent studies show that only about 20% to 30% of eligible cancer patients in the United States receive comprehensive genomic profiling.

STAT News reported on a study published in JAMA Oncology that analyzed testing rates among over 100,000 patients with advanced cancers from 2018 to 2022. The study found lower testing rates among older patients, those in rural areas, and individuals from underserved communities. Reasons for low adoption include insurance coverage limitations and clinician unfamiliarity with testing protocols.

For instance, Medicare covers genomic testing for certain cancers but not all, leading to variability in application. Patients with metastatic disease, where testing is most beneficial, still face delays or omissions in receiving these tests.

genomic testing, patients may miss opportunities for therapies that extend survival or reduce side effects compared to standard chemotherapy.

STAT News highlighted that for cancers like non-small cell lung cancer, testing identifies actionable mutations in up to 50% of cases. Ongoing efforts by organizations like the American Society of Clinical Oncology aim to standardize testing recommendations. Looking ahead, expanded insurance mandates and educational programs could increase testing rates.

Clinical trials continue to develop new targeted therapies, underscoring the need for broader genomic assessment. Health systems are exploring ways to integrate testing into routine care pathways to address current gaps.